AzTrials
AzTrials

Pulmonary Hypertension, Familial Persistent, of the NewbornPhase 3NCT01720524

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

A Phase 3 study testing iv sildenafil in people with Pulmonary Hypertension, Familial Persistent, of the Newborn, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 42 sites in 12 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn. Read more about this study

Who is it for?
Ages 0 to 4 days
What is being tested?
iv sildenafil
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
59 participants
Where
42 sitesin 12 countries
Study dates
5 Aug 2013to 28 Sep 2020
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 0 to 4 days
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Neonates with persistent pulmonary hypertension of the newborn
  • Age <=96 hours and >=34 weeks gestational age
  • Oxygenation Index >15 and <60
  • Concurrent treatment with inhaled nitric oxide and >=50% oxygen

Who cannot join

  • Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary resuscitation
  • Expected duration of mechanical ventilation <48 hours
  • Profound hypoxemia
  • Life-threatening or lethal congenital anomaly

Trial locations and contacts

42 sites in 12 countries.

42 sites in 12 countries

United States20 sites
  • Fairview Hospital

    Cleveland, Ohio, 44111

  • Cleveland Clinic

    Cleveland, Ohio, 44195

  • Duke University Medical Center (DUMC)

    Durham, North Carolina, 27710

  • Indiana University Health Methodist Hospital

    Indianapolis, Indiana, 46202

  • Riley Hospital for Children at IU Health

    Indianapolis, Indiana, 46202

  • Sydney and Lois Eskenazi Hospital

    Indianapolis, Indiana, 46202

  • Children's Mercy Hospitals & Clinics

    Kansas City, Missouri, 64108

  • Arkansas Children's Hospital

    Little Rock, Arkansas, 72202

  • Vanderbilt Children's Hospital

    Nashville, Tennessee, 37232

  • OU Follow-Up Program, PREMIEr Clinic, Children's Hospital

    Oklahoma City, Oklahoma, 73104

  • OU Neonatal Intensive Care Unit at Children's Hospital

    Oklahoma City, Oklahoma, 73104

  • The University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104

  • University of California Davis Medical Center

    Sacramento, California, 95817

  • University of California Davis

    Sacramento, California, 95817

  • University of California Davis Medical Center

    Sacramento, California, 95825

  • Seattle Children's Research Institute

    Seattle, Washington, 98101

  • Seattle Childrens Hospital

    Seattle, Washington, 98105

  • Henry Zarrow Neonatal Intensive Care Unit, Children's Hospital at Saint Francis

    Tulsa, Oklahoma, 74136

  • Warren Cancer Research Foundation

    Tulsa, Oklahoma, 74136

  • Children´s National Medical Center

    Washington D.C., District of Columbia, 20010

Other trials in United States

France5 sites
  • Centre Hospitalier et Regional de Lille - Hopital Jeanne de Flandre

    Lille, 59037

  • Centre Hospitalier et Régional de Lille,

    Lille, 59037

  • Hôpital de la Conception Assistance Publique-Hôpitaux de Marseille

    Marseille, 13385

  • CHU Robert Debré

    Paris, 75019

  • Hopital NECKER - Enfants Malades

    Paris, 75743

Other trials in France

United Kingdom4 sites
  • St. Michael's Hospital

    Bristol, BS2 8EG

  • Leicester Royal Infirmary

    Leicester, LE1 5WW

  • Glenfield Hospital, University Hospitals of Leicester NHS Trust

    Leicester, LE3 9QP

  • Great Ormond Street Hospital NHS Foundation Trust

    London, WC1N 3JH

Other trials in United Kingdom

Belgium2 sites
  • Universitair Ziekenhuis Antwerpen

    Edegem, 2650

  • UZ Gent

    Ghent, 9000

Other trials in Belgium

Denmark2 sites
  • Aarhus Universitetshospital, Skejby

    Aarhus N, 8200

  • Neonatalklinikken Rigshospitalet, 5024

    Copenhagen Ø, 2100

Other trials in Denmark

Netherlands2 sites
  • Radboud University Nijmegen Medical Centre

    Nijmegen, 6525 GA

  • Erasmus MC, Sophia Children's hospital

    Rotterdam, 3015 CN

Other trials in Netherlands

Spain2 sites
  • Hospital Sant Joan de Deu

    Esplugues de Llobregat, Barcelona / Spain, 08950

  • Hospital General Universitario Gregorio Marañon

    Madrid, 28007

Other trials in Spain

Canada1 site
  • CHUL du CHU de Quebec

    Québec, Quebec, G1V 4G2

Other trials in Canada

Germany1 site
  • University Hospital of Leipzig

    Leipzig, 04103

Other trials in Germany

Italy1 site
  • Neonatologia Fondazione IRCCS Policlinico San Matteo

    Pavia, 27100

Other trials in Italy

Norway1 site
  • Haukeland University Hospital

    Bergen, Haukeland, 5000

Other trials in Norway

Sweden1 site
  • Karolinska University Hospital

    Stockholm, 171 76

Other trials in Sweden

About this study

Official title: A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) OR HYPOXIC RESPIRATORY FAILURE AND AT RISK FOR PPHN, WITH A LONG TERM FOLLOW-UP INVESTIGATION OF DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS AFTER COMPLETION OF STUDY TREATMENT

This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.

Being tested
placebo, iv sildenafil
Keywords
persistent pulmonary hypertension, newborn, neonates, iv sildenafil, hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn
Medical subject headings
Persistent Fetal Circulation Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • placeboDrug

    IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.

  • iv sildenafilDrug

    Also called revatio

    loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.

Study groups in NCT01720524
Study groupRoleWhat they receive
placeboPlacebo comparatoriv placebo of normal saline or 10% dextrose
Receives: Drug: placebo
sildenafilExperimentalActive study drug
Receives: Drug: iv sildenafil

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure

    Time in days, on iNO treatment, for participants without iNO treatment failure, was calculated 14 days from the initiation of IV study drug or hospital discharge, whichever occurred first. iNO treatment failure was defined as need for additional treatment targeting PPHN, need for extra corporeal membrane oxygenation (ECMO), or death during the study.

    Measured: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)

  2. Treatment Failure Rate

    Treatment failure rate was defined as percentage of participants who needed additional treatment targeting PPHN, needed ECMO, or died during the study.

    Measured: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)

Secondary outcomes (30)
  1. Time From Initiation of Intravenous (IV) Study Drug to Final Weaning of Mechanical Ventilation

    Time in days, from initiation of IV study drug to final weaning of mechanical ventilation among participants achieving final weaning of mechanical ventilation for PPHN was evaluated. Kaplan-Meier method was used for estimation. For participants with mechanical ventilation beyond 336 hours (14 days) from initiation of IV study drug, data was censored at 14 days.

    Measured: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)

  2. Time From Initiation of Intravenous (IV) Study Drug to First Treatment Failure

    Time in days, from initiation of IV study drug to first treatment failure (defined as need for additional treatment targeting PPHN, need for ECMO, or death) for participants with treatment failure was evaluated. Kaplan-Meier method was used for estimation. For participants without treatment failure by the endpoint assessment date, data was censored at the endpoint assessment date.

    Measured: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)

  3. Percentage of Participants With Individual Components of Treatment Failure

    Percentage of participants with individual components of treatment failure (need to start additional treatment targeting PPHN, need to start ECMO, or death) were evaluated. Some participants could have had multiple qualifying events for treatment failure.

    Measured: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)

  4. Change From Baseline in Oxygenation Index (OI) at Hours 6, 12 and 24 Post-Infusion

    Oxygenation index was calculated as the product of fraction of inspired oxygen (FiO2) and mean airway pressure divided by partial pressure of oxygen dissolved in arterial blood (PaO2) [(FiO2*mean airway pressure)/PaO2] measured in centimeter of water per millimeter of mercury (cmH2O/mmHg). FiO2 is the measure of oxygen concentration that is breathed. Mean airway pressure is defined as an average of the airway pressure throughout the respiratory cycle. PaO2 is the measure of oxygen level dissolved in the arterial blood.

    Measured: Baseline, Hours 6, 12 and 24 after start of infusion

  5. Change From Baseline in Differential Saturation at Hours 6, 12 and 24 Post-Infusion

    Differential oxygenation saturation is a simple way to detect the right-to left shunting at ductus arteriosus using 2 pulse oximeters. It is the difference between pre-ductal and post-ductal sites pulse oxygen saturation (SpO2). Where, pre-duct refers to right upper extremity and post-duct refers to lower limb. Oxygenation saturation is measured as percentage of hemoglobin binding sites occupied by oxygen in the blood.

    Measured: Baseline, Hours 6, 12 and 24 after start of infusion

  6. Change From Baseline in Ratio of Partial Pressure of Oxygen in Arterial Blood to Fraction of Inspired Oxygen (P/F) at Hours 6, 12 and 24

    The ratio of partial pressure of arterial oxygen to fraction of inspired oxygen is a ratio between the oxygen level in the arterial blood and the oxygen concentration that is breathed. It helps to determine the degree of any problems with how the lungs transfer oxygen to the blood.

    Measured: Baseline, Hours 6, 12 and 24 after start of infusion

  7. Maximum Plasma Concentration (Cmax) of Sildenafil and Its Metabolite

    Cmax was obtained for Sildenafil and its major metabolite UK-103,320.

    Measured: Loading dose, Day 1: prior to the start of infusion, 5, 30 minutes after end of loading infusion; Maintenance dose: 48 to 72, 96 to 120 hours during infusion and immediately prior to end of maintenance infusion (up to maximum on Day 14)

  8. Total Plasma Clearance (CL) of Sildenafil and Its Metabolite

    CL is volume of the body fluid/ plasma from which the drug or the metabolite is completely removed per unit time. CL was obtained for Sildenafil and its major metabolite UK-103,320.

    Measured: Loading dose: prior to the start of infusion, 5, 30 minutes after end of loading infusion on Day 1; Maintenance dose: between 48 to 72, 96 to 120 hours during infusion and immediately prior to end of infusion on Day 1

  9. Central Volume of Distribution (Vc) of Sildenafil and Its Metabolite

    Vc is the hypothetical volume into which a drug or a metabolite initially distributes upon administration. It was determined by using a population-based analysis, non-linear mixed-effects modeling (NONMEM), version 7.4.0. Vc was calculated for Sildenafil and its major metabolite, UK-103,320.

    Measured: Loading dose: prior to the start of infusion, 5, 30 minutes after end of loading infusion on Day 1; Maintenance dose: between 48 to 72, 96 to 120 hours during infusion and immediately prior to end of infusion on Day 1

  10. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent are events between first infusion of study drug and up to 31 days after end of study drug infusion (up to 45 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.

    Measured: Baseline up to 31 days after end of study drug infusion (up to 45 days)

  11. Number of Treatment-Emergent Adverse Events (AEs) According to Severity

    AE: untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent are events between first infusion of study drug and up to 31 days after end of study drug infusion (up to 45 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. Severity criteria: mild=did not interfere with subject's usual function; moderate=interfered to some extent with participant's usual function and severe=interfered significantly with participant's usual function. Missing baseline severities were imputed as mild.

    Measured: Baseline up to 31 days after end of study drug infusion (up to 45 days)

  12. Number of Participants With Laboratory Abnormalities

    Criteria for laboratory values: Hematology: hemoglobin, hematocrit, red blood cell count <0.8*lower limit of normal (LLN), platelets<0.5*LLN, >1.75*upper limit of normal (ULN), white blood cells count <0.6*LLN, >1.5*ULN; Liver function: total and direct bilirubin >1.5*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase >3.0*ULN, total protein <0.8*LLN, >1.2*ULN; Renal function: blood urea nitrogen, creatinine >1.3*ULN; Electrolytes: sodium <0.95*LLN, >1.05*ULN, potassium, chloride, calcium, bicarbonate (venous) <0.9*LLN, >1.1*ULN.

    Measured: Up to 14 days from initiation of study drug infusion

  13. Part B: Composite Scores of Cognitive, Language, and Motor Developmental Progress of Participants as Assessed by Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)

    Bayley-III assesses infant and toddler development across five domains: cognitive, language, motor, social-emotional (SE), and adaptive behavior (AB). Assessments of the cognitive, language, and motor domains conducted using items administered to the child; assessments of the SE and AB domains conducted using the primary caregiver's responses to a questionnaire. Score ranges: cognitive scale 0-91, language scale 0-97 and motor scale 0-132, where higher scores indicated better cognitive function, communication and motor skills respectively. Raw scores of cognitive, language and motor domains were converted to composite scores. Composite scores of cognitive, language and motor developmental scales ranged from a scale of 40 to 160, where higher score indicated stronger skills and abilities. In this outcome measure composite scores for infants and toddlers were reported at month 12 and 24.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  14. Part B: Composite Scores of Social-Emotional and Adaptive Behavior Questionnaire as Assessed by Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)

    The Bayley-III assesses infant and toddler development across five domains: cognitive, language, motor, social-emotional (SE), and adaptive behavior (AB). Assessments of the cognitive, language, and motor domains conducted using items administered to the child; assessments of the SE and AB domains conducted using the primary caregiver's responses to a questionnaire. The questionnaire comprises the SE scale (35 items) and the AB scale (241 items). Raw scores of SE and AB were converted to composite scores. Composite scores for SE and AB scale ranged from 40 to 160, where higher scores indicated better social-emotional skills and adaptive behavior in child. In this outcome measure composite scores for parent/caregiver were reported at month 24.

    Measured: Month 24 after end of study treatment in Part A (Day 1 to 14)

  15. Part B: Number of Participants With Eye Movement Disorders as Assessed by Eye Examination

    Standard age-appropriate ophthalmological examinations were used to assess eye movement disorders (presence of amblyopia, strabismus, and nystagmus) at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to eye movement disorder categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  16. Part B: Visual Acuity of Verbal Participants as Assessed by Ophthalmological Assessment

    Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children able of verbal interaction) through visual acuity chart (VAC) quantitative, counting finger (CF), hand motion (HM), light perception (LP), no light perception (NLP) and missing at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual acuity categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  17. Part B: Visual Acuity of Non-Verbal Participants as Assessed by Ophthalmological Assessment

    Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children unable of verbal interaction) through fixates and follows (included central, steady and maintained), light perception (wince to light), no light perception, and missing at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual acuity categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  18. Part B: Visual Acuity of Verbal Participants as Assessed by LogMAR Through Visual Acuity Chart

    Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children able of verbal interaction) at month 12 and 24. Visual acuity (VA) of verbal children was assessed for each eye using the Snellen method, where logarithm of minimum angle of resolution (logMAR) units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal, logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  19. Part B: Visual Status of Participants With Abnormality as Assessed by Eye Examination of the Anterior and Posterior Segments

    Standard age-appropriate ophthalmological examinations were used to assess examination of anterior and posterior chamber for abnormality in lids, conjunctiva, cornea, anterior chamber, lens, iris, pupil, extraocular muscle movement and eye movements at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual status categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  20. Part B: Audiological Status of Participants as Assessed by Behavior Hearing Assessment Through Pure Tone Audiometry Test

    Audiological evaluations of participants were recorded and reported using behavior hearing assessment through pure tone audiometry test which includes participants with normal, abnormal, incomplete/inconclusive behavior at month 12 and 24.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  21. Part B: Audiological Status of Participants as Assessed by Bone Conduction Through Pure Tone Audiometry Test

    Audiological evaluations of participants were recorded and reported by bone conduction assessment through pure tone audiometry test which included participants with sensorineural hearing loss, conductive hearing loss, mixed hearing loss, neural, and unspecified at month 12 and 24. Rows according to bone conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  22. Part B: Audiological Status of Participants as Assessed by Air Conduction Via Phones/Headphones Through Pure Tone Audiometry Test

    Audiological evaluations of participants were recorded and reported by air conduction via phones/headphones through pure tone audiometry test which included participants with hearing loss ranged from less than or equal to (<=) 20 decibel hearing loss (DB HL), 21-40 DB HL, 41-70 DB HL, 71-90 DB HL, greater than (>) 90 DB HL or no response, and missing at frequencies ranged from 500 Hertz (Hz) to 8000 Hz at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately. Rows according to air conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  23. Part B: Audiological Status of Participants as Assessed by Air Conduction Via Soundfield Through Pure Tone Audiometry Test

    Audiological evaluations of participants were recorded and reported by air conduction via soundfield through pure tone audiometry test which included participants with hearing loss ranged from <=20 DB HL, 21-40 DB HL, 41-70 DB HL, 71-90 DB HL, >90 DB HL or no response, and missing at frequencies ranged from 500 Hz to 4000 Hz at month 12 and 24. Rows according to air conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  24. Part B: Audiological Status of Participants as Assessed by Tympanometry Assessment (Peak Pressure) Through Immittance Audiometry Test

    Audiological evaluations of participants were recorded and reported by tympanometry assessment through immittance audiometry test which included participants with peak pressure signs (+) and (-) at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  25. Part B: Audiological Status of Participants as Assessed by Tympanometry Assessment (Static Acoustic Admittance) Through Immittance Audiometry Test

    Audiological evaluations of participants were recorded and reported by tympanometry assessment through immittance audiometry test which included participants with static acoustic admittance at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  26. Part B: Audiological Status of Participants as Assessed by Ipsilateral Stapedial Reflex Through Immittance Audiometry Test

    Audiological evaluations of participants were recorded and reported by ipsilateral stapedial reflex through immittance audiometry test which included participants with presence of ipsilateral stapedial reflex at frequencies ranged from 500 Hz to 2000 Hz at month 12 and 24. Ipsilateral stapedial reflex measures are used to assess the neural pathway surrounding the stapedial reflex, which occurs in response to a loud sound (70 to 90 decibel above threshold). In this outcome measure, data have been reported for right and left ear separately.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  27. Part B: Audiological Status of Participants as Assessed by Transient Evoked Emission Through Otoacoustic Emissions Assessment

    Audiological evaluations of participants were recorded and reported by transient evoked emission through otoacoustic emissions assessment which included participants with presence of transient evoked emissions from frequencies 1000 Hz to 4000 Hz at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  28. Part B: Audiological Status of Participants as Assessed by Distort Product Through Otoacoustic Emissions Assessment

    Audiological evaluations of participants were recorded and reported by distort product through otoacoustic emissions assessment which included participants with presence of distort product at frequencies ranged from 2000 Hz to 8000 Hz at month 12 and 24. Distortion-product otoacoustic emissions (DPOAEs) are generated in the cochlea in response to two tones of a given frequency and sound pressure level presented in the ear canal. Distort product otoacoustic emissions are an objective indicator of normally functioning cochlea outer hair cells. In this outcome measure, data have been reported for right and left ear separately.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  29. Part B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Deaths

    An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. AEs included both serious and all non-serious AEs.

    Measured: up to 24 months after end of study treatment in Part A (maximum up to 26 months)

  30. Part B: Neurological Progress of Participants as Assessed by the Neurology Optimality Score

    The Hammersmith Infant Neurological Examination (HINE) was a standard scoring examination to assess development of cranial nerve; posture; movement; tone; and reflexes and reaction. HINE exam global score is a sum of subset (cranial nerve, posture, movement, tone, reflexes and reactions) scores, ranged from 0 to 78, where higher score represents better outcome. Here, the HINE global scores were reported at month 12 and 24.

    Measured: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Nov 2012 (estimated)
  2. Study start5 Aug 2013
  3. Primary completion17 Oct 2018
  4. Study completion28 Sep 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
59 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01720524
Sponsor's protocol ID
A1481316
Other IDs
2012-002619-24
Status last verified
Aug 2021
First submitted
17 Sep 2012
Last updated
16 Aug 2021
Data monitoring committee
Yes
Individual data sharing
Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Publications

  • Pierce CM, Zhang MH, Jonsson B, Iorga D, Cheruvu N, Balagtas CC, Steinhorn RH. Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial. J Pediatr. 2021 Oct;237:154-161.e3. doi: 10.1016/j.jpeds.2021.05.051. Epub 2021 May 27.

    PubMed 34052232

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing iv sildenafil in people with Pulmonary Hypertension, Familial Persistent, of the Newborn, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 42 sites in 12 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 42 sites in United States, France, United Kingdom, Belgium, Denmark and 7 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 25 Mar 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure (time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01720524, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Aug 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in